AI-guided nutrition helped more patients hit intake targets—but was AI the reason?
In a 90-patient randomized trial after gastrointestinal cancer surgery, a multicomponent AI-guided programme improved 30-day energy and protein intake. It did not isolate AI from individualization, targets or clinician review.
The short version
- What happened
- Ninety patients were randomized 1:1 after laparoscopic gastric or colorectal cancer surgery, and all completed the 30-day follow-up.
- Who it affects
- Patients received more specific guidance after major cancer surgery, but the study does not show that a model can safely replace a dietitian or that better 30-day intake improves longer-term recovery.
- What remains unproven
- Single centre
Keep in mind
Single centre
90 patients
30-day follow-up
Multicomponent intervention
AI effect not isolated
Participants and delivery staff unblinded
Not powered for clinical complications
Source analysis · 1 linked source. Primary analysed source date: 29 October 2026.
Keep following the evidence
Join The Impact Brief founding list for selected AI reports, their effect on people and the evidence limits. Read a sample first.
Read the full report · 4 min The evidence, methods, implications and limitations
More patients reached the short-term intake target
A randomized trial in China found that more patients recovering from gastrointestinal cancer surgery reached prescribed energy and protein targets after receiving an AI-facilitated nutrition plan. Of 90 adults undergoing laparoscopic gastric or colorectal cancer surgery, 45 received the programme and 45 received the hospital's standard generic discharge advice. All completed the 30-day follow-up. Energy adequacy—the prespecified primary outcome, defined as at least 90% of a target of 25–30 kilocalories per kilogram per day—was reached by 66.7% in the intervention group and 40.0% in standard care. The odds ratio was 3.0, with a 95% confidence interval from 1.3 to 7.1.
Protein adequacy, defined as at least 1.2 grams per kilogram per day, was reached by 62.2% and 35.6% respectively, an odds ratio of 2.9 with a 95% confidence interval from 1.2 to 6.8. Blinded dietitians calculated intake from three-day food records during the fourth week after discharge. Patients in the intervention group also reported less fatigue, nausea or vomiting, appetite loss and gastrointestinal symptoms. Provider time averaged 8.2 minutes, compared with 12.5 minutes for standard advice.[1]
The comparison tested a package, not an AI ingredient
The intervention was not simply a chatbot answering questions. A nurse entered surgical details, laboratory values, diet tolerance and cultural preferences into an Analysis–Blueprint–Concrete Plan prompt for DeepSeek v3.2. The output included quantified energy, protein and fluid targets, phased written advice and a clinician safety review before delivery. Standard care was a one-page generic handout with brief verbal guidance and no routine individualization or quantified targets.
That contrast makes the result useful as a test of the combined service, but weak evidence that AI was the active cause. Individualized counselling, written targets, longer guidance or the structured review could each have contributed. Participants and staff delivering the intervention were not blinded, although dietitians assessing intake, laboratory staff and the statistician were. The study was powered for dietary adequacy, not complications, and lasted only 30 days.[1]
The distinction that matters
What changed at 30 days
The randomized comparison measured target achievement, not long-term recovery.
Energy
66.7% vs 40.0% reached at least 90% of target
27-point difference
Protein
62.2% vs 35.6% reached 1.2 g/kg/day
27-point difference
Clinical outcomes
No significant weight, serum-marker or complication difference
Longer-term benefit unproven
Better intake did not yet mean better recovery
There were no statistically significant differences in weight change, serum albumin, haemoglobin or postoperative complications. Weight loss averaged 2.1% in the intervention group and 2.5% in standard care. Complications occurred in roughly one fifth of each group. Those results do not prove equivalence; with 90 patients, uncommon harms or modest clinical benefits could easily be missed. Readmissions were also too uncommon for a dependable comparison.
For patients and clinical teams, the practical promise is a quicker way to assemble specific, reviewable discharge guidance. It is not permission to let a model prescribe nutrition without oversight. Confidence would rise with a larger multicentre trial that compares AI-assisted guidance with equally individualized, quantified human counselling, follows weight and clinical outcomes for longer, and measures errors, staff workload and patient understanding. Until then, the trial supports the package's short-term effectiveness, not an independent AI advantage or improved recovery.[1]
Watch the background, then check the evidence
Illustrative photo · not a video frame
The Royal Society · 44 min 28 sec · Background explainer
Is this the AI future we want? | The Royal Society
YouTube loads only when you choose; playback starts when you press play.
A Royal Society discussion with Madhumita Murgia and biomedical engineer Alison Noble on AI’s potential in healthcare, science and culture, recorded at the 30 June 2026 event.
Evidence check: A discussion of opportunities and risks, including future possibilities. It is not evidence that every application described is available or clinically proven.
Published 2026-07-01. Source checked 14 October 2026. Check captions on the publisher’s video page.
Check the healthcare evidencePhoto: Daniel Sone / National Cancer Institute / Unsplash · Licence
Continue the story
Read next
Continue exploring clinical ai: compare the finding and its evidence limits.
Cancer-fever model travelled to a second hospital—but still needs a treatment trial
A model developed on 987 German hospital stays and tested on 7,409 US stays predicted whether fever would persist after antibiotics, with external AUROC 0.78. Retrospective opportunity counts do not show that withholding escalation is safe.
Read the next reportExplore the full source and evidence record
What this means for people
- Patients received more specific guidance after major cancer surgery, but the study does not show that a model can safely replace a dietitian or that better 30-day intake improves longer-term recovery.
Global context
Post-discharge food access, diets, clinical staffing and cancer pathways differ across health systems. A plan that worked with Chinese-language prompting and local clinician review needs testing against equally strong human counselling elsewhere.
What the evidence does not yet show
- Single centre
- 90 patients
- 30-day follow-up
- Multicomponent intervention
- AI effect not isolated
- Participants and delivery staff unblinded
- Not powered for clinical complications
What to watch next
- Multicentre replication
- AI versus equally individualized human counselling
- Longer-term weight and clinical outcomes
- Safety corrections
- Patient understanding
- Staff workload
- Different diets and languages
Living evidence record
Impact record IAI-1D7FSOR
Evidence stage
Studied
Confidence
Supported
Reporting basis
Source analysis
Independent or research support
Present
Record status
Monitoring
Last checked
30 October 2026
Source trail
1 direct source across 1 source type.
People impact
Documented in this record.
Uncertainty
Limits and next checks are explicit.
Stages describe the evidence available—not whether a technology is good or bad. See the public method.
Single-source reporting disclosure
This record analyses one direct source. It can establish what Supportive Care in Cancer published or reported, but it is not independent corroboration of every performance claim or predicted outcome. The confidence label will change only when broader evidence is added.
Evidence trail
Sources used for this report
Links checked 30 October 2026
Research question, topics and regions
AI-facilitated individualized nutrition guidance after gastrointestinal cancer surgery
Topics: Clinical AI · Cancer care · Nutrition · Randomized trial · Discharge support
Regions: China · Asia · Global
This report is labelled source analysis. We summarise and analyse source material in our own words; company statements remain attributed claims until independently supported. Translated summaries preserve the meaning of the original source and link back to it. Read our editorial standards.
Reader commentary
What does this mean where you are?
Tell us what you have seen at work, in your community or in everyday life. A question is welcome too. No account is needed; we review notes before publishing them.
Explore commentary across the portal →Published reader notes
0No published reader notes yet. You can start the evidence-led discussion above.
Prefer a private correction or response? Contact the newsroom.